阿托伐他汀的药物基因组学研究进展  

Advances in search for pharmacogenomics of atorvastatin

作　　者：贺宝霞[1,2] 石磊[2] 赵树进[2] 

机构地区：[1]河南省肿瘤医院药剂科,郑州450008 [2]广州军区广州总医院药学部,广州510010

出　　处：《中国临床药理学杂志》2011年第11期888-891,共4页The Chinese Journal of Clinical Pharmacology

基　　金：广东省科技计划基金资助项目(2009B080701105)

摘　　要：阿托伐他汀是目前临床上广泛使用的口服降脂药,其对冠心病的一级和二级预防具有重要作用;但其疗效以及不良反应存在显著的个体差异,这与药物相关基因的多态性有关。本文主要介绍了基因多态性在阿托伐他汀的代谢、转运以及不良反应等方面的作用。Atorvastatin is widely used as an oral lipid-lowering drug and it has an important role in the prevention of coronary heart disease.However,wide interindividual variations exist in the plasma lipid response to statin treatment including atorvastatin,which may due to drug-related gene polymorphism.This review states the effect of gene polymorphism on the aspect of metabolism,transportation,receptor,and adverse effect based on literature and cases in recent years,which can help provide reference for individualized treatment.

关 键 词：阿托伐他汀 基因多态性 药物基因组学 

分 类 号：R972.6[医药卫生—药品] R968[医药卫生—药学]